Takeda is Japan's biggest pharmaceutical company, and has spent the past few years establishing a stronger local presence in key international markets such as the US and Europe, where previously it had relied on partners to handle its products. For several years its main presence in the US was through TAP Products, a joint venture with Abbott Laboratories which distributed Takeda's Prevacid and other products in North America. This partnership was dissolved in 2008, and Takeda established its own direct presence in the region, in part through the acquisition of local biotech Millennium Pharma. Another key development was the acquisition in 2011 of Swedish drug developer Nycomed, which had a strong presence of its own in Europe and emerging markets. Takeda's top-selling product in year ending 2016 was oncology drug Velcade, with US sales topping $1bn. (Johnson & Johnson has international rights). With Velcade's patent due to expire in 2017, the group has launched a follow-up product, Ninlaro. Other key drugs include prostate and breast cancer treatment Leuprorelin, and heartburn products Pantoprazole and Lansoprazole (or Prevacid). Entyvio, to treat colitis and Crohn's disease, is the group's fastest-growing launch, with sales tripling in 2015. In early 2017, the group acquired US biotech Ariad, makers of leukaemia drug Iclusig, for $5.2bn. Takeda also has a sizeable OTC healthcare business in its domestic market, with brands such as Alinamin vitamin supplements and cold remedy Benza. It also has rights to several Johnson & Johnson brands including Nicorette. CEO Yasuchika Hasegawa retired in 2014 to be succeeded by Christophe Weber, the first non-Japanese to lead the group. Revenues in the year to March 2016 were around $15.0bn. Takeda traces its roots all the way back to 1781, when founder Chobei Takeda began selling traditional herbal remedies. Adbrands does not currently profile this company but subscribers may access account assignments and contact information. The searchable account assignments database is available to full subscribers to Adbrands.net premium services. Click here to access Adbrands account assignments (subscribers only); or see here for information on how to subscribe.
Which agencies handle advertising for Takeda? Find out more from Adbrands Account Assignments
Who are the competitors of Takeda? See Pharmaceutical Sector index for other companies
Capsule checked 6th July 2016
Recent stories from Adbrands Weekly Update:
Adbrands Weekly Update 26th Apr 2018: Pharma group Takeda is close to pulling off Japan's biggest-ever takeover of a Western company, having finally secured a hesitant acceptance by Ireland-based rival Shire. Takeda has raised its bid four times in the past week to counter threats of a rival offer from Allergan (which disappeared almost as soon as it was rumoured) as well the company's own shrinking share price. Shire agreed on Wednesday to recommend the latest bid, worth around $64bn in cash and stock, to its shareholders. If the deal goes through, the merged group would become the world's 8th largest drug company by revenues, generating around half its sales in the US. The deal still has to be approved by both groups' boards and is subject to due diligence.
Adbrands Weekly Update 18th Apr 2018: Japanese drug company Takeda appears to be getting serious about making a bid for Shire, the Irish pharmaceutical group that has long been seen as a potential target for one rival or another. Rumours first surfaced at the end of March, but Takeda is now said to be talking to banks about raising the $50bn or so that a successful takeover would require. A successful bid would catapult Takeda into the top ranks of the world's drugmakers. Combined sales of around $33bn would put the merged company into the top six pharma groups globally, ahead even of GSK. Takeda's top products currently are oncology drug Velcade and gastro-enterology treatment Entyvio; Shire's is the ADHD treatment Vyvanse. However, Shire is currently slightly larger than Takeda by revenues and also more valuable by market cap. A formal bid by Takeda could flush out an even bigger rival bidder, like Pfizer or Amgen. Meanwhile, Shire itself appeared to take a defensive move by disposing of a collection of oncology drugs - in which Takeda had expressed interest - to French group Servier for $2.4bn.
Adbrands Weekly Update 10th Apr 2014: Japanese drug company Takeda Pharmaceuticals may have to pay as much as $9bn in punitive damages after a US court found it had hidden indications that patients taking its diabetes blockbuster Actos, whose patent expired in 2011, had a higher risk of dveloping cancer. Takeda was handed a fine of $6bn, but may also have to cover an additional $3bn damages awarded against Eli Lilly, which co-marketed the drug in the US from 1999 to 2006. Lilly claims it is indemnified against any such fines under the terms of its original agreement with Takeda. Both companies disagreed with the verdict and will appeal the fines, a new record for the pharmaceutical industry.
Adbrands Company Profiles assess more than 1,000 leading advertisers, brands and agencies, and examine each company's business record, geographic strength and comparative performance within its chosen sector, including strengths and weaknesses, history, up-to-date news and top-line financial information. What else does the company do? How did it originate? What other brands does it own? How is it performing in the market? With what other businesses is it affiliated?
Adbrands Account Assignments is a database tracking account management for the world's leading brands and companies. In other words, which advertising agency handles which accounts in which countries. Fully searchable by brand, brandowner company or advertising agency, the database now contains more than 15,000 worldwide account assignments for over 4,000 leading brands.
New to the industry? See here for a brief summary of how the agency business is structured.
All rights reserved © Mind Advertising Ltd 1998-2018